Anticoagulation and Antithrombotic
โ ๏ธ Safety Alert: Always monitor for a platelet fall (>50% or to <150) between days 5โ14 of heparin exposure โ may signal Heparin-Induced Thrombocytopenia (HIT), which is pro-thrombotic, not bleeding-related.
โก๏ธ Stop all heparin immediately and seek urgent haematology advice.
๐ About - ALWAYS CHECK BNF / Local Policy
- ๐ Antithrombotics and anticoagulants are high-risk drugs: life-saving when used correctly, catastrophic when misused.
- โ ๏ธ Long-term anticoagulation carries a major bleeding risk โ 3โ4% per year, with mortality โ 0.5% per year.
- ๐จโโ๏ธ Always involve senior or haematology advice in complex cases (peri-operative care, renal failure, pregnancy, malignancy).
- ๐ Document indication, duration, review date, and bleeding risk clearly.
๐ฉธ Antithrombotic (Antiplatelet) Drugs
- Aspirin ๐ข
โข Loading: 300 mg stat โ Maintenance: 75 mg OD
โข Uses: ACS, post-MI, secondary stroke prevention
โข Adverse effects: GI irritation, bleeding โ consider PPI
- Clopidogrel ๐ข
โข Loading: 300โ600 mg (ACS) โ 75 mg OD
โข NICE-preferred for secondary stroke prevention
โข CYP2C19 interaction โ reduced effect with omeprazole
- Dipyridamole MR ๐ก
โข 200 mg BD (modified release)
โข Historical role with aspirin - now largely replaced by clopidogrel
- Dual Antiplatelet Therapy (DAPT) ๐ฅ
โข Aspirin + clopidogrel (or ticagrelor) post-ACS / stenting
โข Time-limited (e.g. 6โ12 months)
โข Not for long-term stroke prevention
๐ Unfractionated Heparin (UFH)
- Used when rapid reversal or short half-life is required (e.g. peri-operative, severe renal failure).
- Administered as IV infusion with weight-based bolus.
- ๐งช Requires close monitoring using aPTT ratio.
- ๐ Fully reversible with Protamine sulfate IV.
| โ๏ธ UFH Adjustment Protocol (Example) |
| aPTT Ratio |
Action |
Recheck |
| <1.3 | Bolus 5000 IU, โ infusion by 5000 IU / 24 h | 6 h |
| 1.3โ1.4 | โ infusion by 5000 IU / 24 h | 6 h |
| 1.5โ2.4 | No change | 12โ24 h |
| 2.5โ3.0 | Stop 30 min, โ by 5000 IU / 24 h | 6 h |
| 3.1โ4.0 | Stop 60 min, โ by 5000 IU / 24 h | 6 h |
| >4.0 | Stop infusion, urgent senior review | 3โ6 h |
๐งท LMWH - Low Molecular Weight Heparin (UK)
- Enoxaparin (Clexane)
โข Prophylaxis: 40 mg SC OD (20 mg if CrCl <30)
โข Treatment: 1 mg/kg BD or 1.5 mg/kg OD
- Dalteparin (Fragmin)
โข Prophylaxis: 5000 IU SC OD
โข Treatment: 200 IU/kg OD (max 18,000 IU)
โข Cancer-associated thrombosis: 200 IU/kg OD ร30 days โ 150 IU/kg OD
- Tinzaparin (Innohep)
โข Prophylaxis: 4500 IU SC OD
โข Treatment: 175 IU/kg OD
๐ Indications for LMWH
- VTE prophylaxis in medical, surgical, and immobile patients.
- Treatment of DVT and PE.
- Preferred anticoagulant in pregnancy and active cancer.
- Acute coronary syndromes (e.g. NSTEMI).
๐ DOACs - Direct Oral Anticoagulants (UK)
- Apixaban (Eliquis)
โข AF: 5 mg BD
โข VTE: 10 mg BD ร7 days โ 5 mg BD
โข Reduce to 2.5 mg BD if โฅ2 of: age โฅ80, weight โค60 kg, creat โฅ133 ฮผmol/L
- Rivaroxaban (Xarelto)
โข AF: 20 mg OD with food
โข VTE: 15 mg BD ร21 days โ 20 mg OD
โข Reduce to 15 mg OD if CrCl 15โ49
- Dabigatran (Pradaxa)
โข AF: 150 mg BD
โข VTE: 150 mg BD after 5โ10 days LMWH
โข Avoid if CrCl <30
- Edoxaban (Lixiana)
โข AF: 60 mg OD
โข VTE: 60 mg OD after LMWH lead-in
โข Reduce to 30 mg OD if CrCl 15โ50 or weight โค60 kg
๐ Indications for DOACs
- Stroke prevention in non-valvular AF.
- Treatment and secondary prevention of DVT / PE.
- Post-operative VTE prevention (hip/knee replacement).
๐ง Makindo clinical pearl:
Always ask WHY the patient is anticoagulated, HOW LONG for, and WHEN it should be reviewed.
Anticoagulants donโt cause bleeding - they unmask it.
๐จ Anticoagulant Reversal Agents (UK)
| Drug |
Reversal Agent |
Dose / Notes |
| Warfarin |
Vitamin K + PCC |
โข Vitamin K 5โ10 mg IV (slow)
โข PCC (Beriplex/Octaplex) per INR & weight
โข Use FFP if PCC unavailable
|
| UFH |
Protamine sulfate |
โข 1 mg protamine per 100 IU heparin (max 50 mg)
โข Give IV slowly (hypotension/anaphylaxis risk)
|
| LMWH |
Protamine (partial) |
โข Partial reversal only
โข 1 mg per 1 mg enoxaparin if within 8 h
|
| Dabigatran |
Idarucizumab |
โข 5 g IV (2 ร 2.5 g)
โข Immediate and complete reversal
|
| Apixaban / Rivaroxaban |
Andexanet alfa* |
โข Specialist use only
โข PCC often used if unavailable
|
โ ๏ธ Makindo safety tip: Reversal decisions depend on bleeding severity, drug timing, and thrombotic risk.
Always involve haematology in major bleeding.
๐ฉธ Major Bleeding on Anticoagulants - Practical Algorithm
- ๐ Stop anticoagulant immediately.
- ๐ง ABCDE approach - early airway protection if needed.
- ๐งช Urgent bloods: FBC, clotting, fibrinogen, U&E, lactate, group & crossmatch.
- ๐ฉธ Activate major haemorrhage protocol if unstable.
- ๐ Give specific reversal agent (see table above).
- ๐งโโ๏ธ Early haematology + specialty input.
- ๐ Reassess need/timing for re-anticoagulation once bleeding controlled.
โ๏ธ Anticoagulants - Quick Comparison
| Feature |
UFH |
LMWH |
DOACs |
Warfarin |
| Onset |
Immediate |
Hours |
Rapid |
Slow (days) |
| Monitoring |
aPTT |
None* |
None |
INR |
| Renal failure |
โ Safe |
โ Dose adjust |
โ Often avoid |
โ Safe |
| Reversal |
โ Protamine |
โ Partial |
โ (agent-specific) |
โ Vit K / PCC |
| Pregnancy |
โ |
โ First-line |
โ Avoid |
โ Teratogenic |
๐ง Makindo final pearl:
If a patient on anticoagulation deteriorates, always ask:
Is this bleeding? Is this HIT? Or is this the disease progressing?
Pattern recognition + physiology beats rote dosing every time.